Competitive edge: HSR mini-series

Welcome back to Norton Rose Fulbright's antitrust and competition webinar series, Competitive edge, hosted by US Head of Antitrust and Competition, Neely Agin.

In this HSR mini-series, Norton Rose Fulbright lawyers from different practice industries will join Neely Agin, Luke McFarland and Mark Angland to discuss key highlights surrounding the FTC's final rule. This rule will significantly change the reporting of mergers and acquisitions under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (also known as the HSR Act), and its nationwide rippling effects on the pharmaceutical and life sciences, healthcare and private equity sectors.

Program 1: Life sciences and pharmaceuticals

Wednesday, November 20, 2024

1:00 – 1:45 pm ET | 12:00 – 12:45 pm CT | 10:00 – 10:45 am PT

Robin Adelstein, Global Head of Antitrust and Competition Co-Head of Commercial Litigation, US will join Neely, Luke and Mark to discuss the final rules' impacts on the pharmaceutical and life sciences industry.

Program 2: Private equity

Thursday, November 21, 2024

11:00 – 11:45 am ET | 10:00 – 10:45 am CT | 8:00 – 8:45 am PT

Ward Atterbury, Partner, will join Neely, Luke and Mark to discuss the final rules' effects in the private equity sector.

Stay tuned for the third webinar program in this mini-series coming soon!

Continuing education information

For those attending the live webinar, this program is eligible for 0.75 Professional Practice CLE Credits in New York and 0.75 General CLE Credits in California, Illinois and Texas.